We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Lexicon Pharmaceuticals Inc | NASDAQ:LXRX | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.04 | 2.42% | 1.69 | 1.68 | 1.70 | 1.75 | 1.65 | 1.73 | 4,643,859 | 00:59:59 |
1. Name and Address of Reporting Person * DEBBANE RAYMOND | 2. Issuer Name and Ticker or Trading Symbol LEXICON PHARMACEUTICALS, INC. [ LXRX ] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below) |
|
3. Date of Earliest Transaction
(MM/DD/YYYY)
|
|
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person |
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned |
||||||||||
1.Title of Security (Instr. 3) |
2. Trans. Date | 2A. Deemed Execution Date, if any |
3. Trans. Code (Instr. 8) |
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) |
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) |
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |||
Code | V | Amount | (A) or (D) | Price | ||||||
Common Stock | 9/13/2019 | P | 200 | A | $2.25 | 13102 | D | |||
Common Stock | 9/13/2019 | P | 400 | A | $2.27 | 13502 | D | |||
Common Stock | 9/13/2019 | P | 300 | A | $2.28 | 13802 | D | |||
Common Stock | 9/13/2019 | P | 300 | A | $2.29 | 14102 | D | |||
Common Stock | 9/13/2019 | P | 800 | A | $2.30 | 14902 | D | |||
Common Stock | 9/13/2019 | P | 500 | A | $2.31 | 15402 | D | |||
Common Stock | 9/13/2019 | P | 2309 | A | $2.32 | 17711 | D | |||
Common Stock | 9/13/2019 | P | 1300 | A | $2.33 | 19011 | D | |||
Common Stock | 9/13/2019 | P | 1101 | A | $2.34 | 20112 | D | |||
Common Stock | 9/13/2019 | P | 1700 | A | $2.35 | 21812 | D | |||
Common Stock | 9/13/2019 | P | 200 | A | $2.355 | 22012 | D | |||
Common Stock | 9/13/2019 | P | 2068 | A | $2.36 | 24080 | D | |||
Common Stock | 9/13/2019 | P | 5494 | A | $2.37 | 29574 | D | |||
Common Stock | 9/13/2019 | P | 400 | A | $2.375 | 29974 | D | |||
Common Stock | 9/13/2019 | P | 28225 | A | $2.38 | 58199 | D | |||
Common Stock | 9/13/2019 | P | 21652 | A | $2.39 | 79851 | D | |||
Common Stock | 9/13/2019 | P | 1200 | A | $2.395 | 81051 | D | |||
Common Stock | 9/13/2019 | P | 152 | A | $2.399 | 81203 | D | |||
Common Stock | 9/13/2019 | P | 34087 | A | $2.40 | 115290 | D | |||
Common Stock | 9/13/2019 | P | 24772 | A | $2.41 | 140062 | D | |||
Common Stock | 9/13/2019 | P | 200 | A | $2.415 | 140262 | D | |||
Common Stock | 9/13/2019 | P | 15582 | A | $2.42 | 155844 | D | |||
Common Stock | 9/13/2019 | P | 900 | A | $2.425 | 156744 | D | |||
Common Stock | 9/13/2019 | P | 18051 | A | $2.43 | 174795 | D | |||
Common Stock | 9/13/2019 | P | 1700 | A | $2.435 | 176495 | D | |||
Common Stock | 9/13/2019 | P | 29880 | A | $2.44 | 206375 | D | |||
Common Stock | 9/13/2019 | P | 100 | A | $2.445 | 206475 | D | |||
Common Stock | 9/13/2019 | P | 3800 | A | $2.45 | 210275 | D | |||
Common Stock | 9/13/2019 | P | 100 | A | $2.455 | 210375 | D | |||
Common Stock | 4321214 | I | By Invus C.V. |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) |
|||||||||||||||
1. Title of Derivate Security (Instr. 3) |
2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any |
4. Trans. Code (Instr. 8) |
5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) |
6. Date Exercisable and Expiration Date |
7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) |
8. Price of Derivative Security (Instr. 5) |
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | ||||
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Explanation of Responses: |
Reporting Owners |
|||||
Reporting Owner Name / Address |
|
||||
Director | 10% Owner | Officer | Other | ||
DEBBANE RAYMOND 8800 TECHNOLOGY FOREST PLACE THE WOODLANDS, TX 77381 |
X |
Signatures |
||
/s/ Raymond Debbane | 9/17/2019 | |
**Signature of Reporting Person | Date |
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | |
* | If the form is filed by more than one reporting person, see Instruction 4(b)(v). |
** | Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
Note: | File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. |
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. |
1 Year Lexicon Pharmaceuticals Chart |
1 Month Lexicon Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions